Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer
19 sept. 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer
Autolus Therapeutics Presents Clinical Data Update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024
27 août 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus presents clinical data update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024
Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO
31 mai 2024 08h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
14 mai 2024 10h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics to present three clinical data updates at the 2024 EHA Congress
Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call
13 mai 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
24 avr. 2024 10h00 HE
|
Autolus Therapeutics plc
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL at ASCO
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
23 avr. 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)
02 avr. 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics announces acceptance of MAA by the EMA for obe-cel for patients with B-ALL
Autolus Therapeutics Announces Changes to its Board of Directors
01 avr. 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics Announces Changes to its Board of Directors
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
14 mars 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates